<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928378</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210051</org_study_id>
    <nct_id>NCT04928378</nct_id>
  </id_info>
  <brief_title>Bone Resistant Tuberculosis</brief_title>
  <acronym>TboneR</acronym>
  <official_title>Management of Osteoarticular Infection Due to Multidrug Resistant Mycobacterium Tuberculosis Strains in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recommendations for the treatment of MDR tuberculosis are based on pulmonary tuberculosis&#xD;
      since there is a lack of specific recommendations for TB bone and osteoarticular disease,&#xD;
      including those due to multi drug resistance strains (MDR IOATB). Given the lack of data&#xD;
      regarding MDR IOATB, it may be helpful to study the diagnosis, medical treatment, surgical&#xD;
      indications and prognosis of a cohort of MDR IOATB patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the lack, in the guidelines regarding bone and osteoarticular infections due to MDR M.&#xD;
      tuberculosis strains, this study aims to characterize the diagnosis, management and outcome&#xD;
      of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).&#xD;
&#xD;
      Aim: descriptive study of diagnosis, therapeutics and outcome of patients with bone and&#xD;
      osteoarticular infection with MDR IOATB in France.&#xD;
&#xD;
      Set up: patients registered in the database of the National Reference Center (CNR) for MDR&#xD;
      IOATB in France, treated for MDR IOATB between January 1, 2007 and December 31, 2018 will be&#xD;
      included and analyzed.&#xD;
&#xD;
      Study design: retrospective study on historical cohort&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">September 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>study of infected population with MDR TB IOATB</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Description of patients with MDR IOATB on anamnestic, clinical, paraclinical, diagnosis, prognosis, therapeutic and outcome level.&#xD;
Data collected for : demographics (age, sex), history of previous treatment for tuberculosis (list of), immunocompromised status (and which kind), clinical presentation, tuberculosis localization, administered treatment (sort, duration), adverse events (number of patients with treatment-related adverse events using WHO scale), surgery (y or n and which surgery: descriptive) and treatment outcomes death, cure, relapse, lost in follow up)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug susceptibility testing</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Testing for phenotypic drug susceptibility using the proportion method and genetic mutations involved in antituberculosis drug resistance identified with biomolecular tool.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bone and Osteoarticular Infection Due to MDR M. Tuberculosis Strains</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Descriptive retrospective study</intervention_name>
    <description>characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients registered in the database of the National Reference Center (CNR) for MDR IOATB in&#xD;
        France, treated for MDR IOATB between January 1, 2007 and December 31, 2018 will be&#xD;
        included and analyzed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient with an MDR IOATB whose sample and / or strain has been referred to the&#xD;
             National Reference Center (CNR) for mycobacteria in France, will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing to have their data used.&#xD;
&#xD;
          -  Patients under guardianship or curatorship, underage patients and patients under legal&#xD;
             protection will not be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Aubry, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Aubry, MD,PhD</last_name>
    <phone>+33 1 40 77 98 67</phone>
    <email>alexandra.aubry@sorbonne-universite.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Aubry, MD, PhD</last_name>
      <phone>+33 1 40 77 98 67</phone>
      <email>alexandra.aubry@sorbonne-universite.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycobacterium tuberculosis</keyword>
  <keyword>Multi drug resistance</keyword>
  <keyword>Bone</keyword>
  <keyword>osteoarticular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

